T1	intervention 10 21	bevacizumab
T2	outcome 1431 1468	grade 3-4 wound-healing complications
T3	eligibility 25 77	metastatic breast cancer patients undergoing surgery
T4	total-participants 796 799	155
T5	total-participants 887 890	672
T6	outcome 982 1004	grade 3 bleeding event
T7	iv-bin-percent 940 944	0.9%
T8	iv-bin-percent 1031 1035	0.9%
T9	outcome 1071 1094	grade 3 bleeding events
T10	iv-bin-abs 1099 1102	one
T11	iv-bin-percent 1112 1116	0.1%
T12	outcome 1132 1154	grade 4 bleeding event
T13	outcome 1159 1182	grade 5 bleeding events
T14	outcome 1249 1283	grade 3 wound-healing complication
T15	control 1324 1331	placebo
T16	cv-bin-abs 1335 1337	46
T17	cv-bin-percent 1339 1343	2.2%
T18	iv-bin-abs 1370 1372	57
T19	iv-bin-percent 1374 1378	1.8%
T20	iv-bin-abs 1407 1409	52
T21	iv-bin-percent 1411 1415	1.9%
T22	iv-bin-percent 1483 1487	2.2%
T23	iv-bin-percent 1492 1496	1.3%
